2405. In vitro Synergistic Activity of Sitafloxacin in Combination With Colistin Against Clinical Isolates of Multidrug-Resistant Acinetobacter baumannii in Thailand (2018)
Title : 2405. In vitro Synergistic Activity of Sitafloxacin in Combination With Colistin Against Clinical Isolates of Multidrug-Resistant Acinetobacter baumannii in Thailand
Researcher : Vipavee Rodjun2,Taniya Paiboonvong1,Jantana Houngsaitong1,Preecha Montakantikul2,
1 Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand
2 Faculty of Pharmacy, Siam University, Bangkok, Thailand
ฐานข้อมูลงานวิจัย มหาวิทยาลัยสยาม : –
Link to article: Open Forum Infectious Diseases, Volume 5, Issue suppl_1, November 2018, Pages S718–S719, https://doi.org/10.1093/ofid/ofy210.2058
Journal : Open Forum Infectious Diseases / Scopus
Citation : Rodjun, V., Paiboonvong, T., Houngsaitong, J., & Montakantikul,P. (2018). 2405. In vitro Synergistic Activity of Sitafloxacin in Combination With Colistin Against Clinical Isolates of Multidrug-Resistant Acinetobacter baumannii in Thailand. Open Forum Infectious Diseases, 5(Suppl 1), S718–S719. https://doi.org/10.1093/ofid/ofy210.2058
A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study (2023)
Title : A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study
Researcher : Apichot So-Ngern,Supunnee Jirajariyavej, Huttaya Thuncharoon, Nuttha Khunthupat, Teerachai Chantarojanasiri and Preecha Montakantikul
Link to article: Clinical and Translational Science, Volume 16, Issue 12, December 2023, Pages 2709-2718. https://doi.org/10.1111/cts.13665
Journal : Clinical and Translational Science / in Scopus
Citation : So-Ngern A, Jirajariyavej S, Thuncharoon H, Khunthupat N, Chantarojanasiri T and Montakantikul P. (2023). A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens: A pilot study. Clinical and Translational Science, 16(12), 2709-2718. https://doi.org/10.1111/cts.13665
ฐานข้อมูลงานวิจัย มหาวิทยาลัยสยาม : https://e-research.siam.edu/kb/a-randomized-controlled-trial-of-prulifloxacin/
Advances in Natural Product Extraction Techniques, Electrospun Fiber Fabrication, and the Integration of Experimental Design: A Comprehensive Review (2023)
Title : Advances in Natural Product Extraction Techniques, Electrospun Fiber Fabrication, and the Integration of Experimental Design: A Comprehensive Review
Researcher : Juthaporn Ponphaiboon, Wantanwa Krongrawa, Wah Wah Aung, Nawinda Chinatangkul,Sontaya Limmatvapirat and Chutima Limmatvapirat
Link to article : Molecules, Volume 28, Issue 13, 5163. https://doi.org/10.3390/molecules28135163
Citation : Ponphaiboon J., Krongrawa W., Aung W.W., Chinatangkul N., Limmatvapirat S., & Limmatvapirat C. (2023). Advances in natural product extraction techniques, electrospun fiber fabrication, and the integration of experimental design: A comprehensive review. Molecules, 28(13), 5163. https://doi.org/10.3390/molecules28135163
Journal : Molecules / in Scopus
ฐานข้อมูลงานวิจัย มหาวิทยาลัยสยาม : https://e-research.siam.edu/kb/advances-in-natural-product/
Anti-aging potential and phytochemicals of Centella asiatica, Nelumbo nucifera, and Hibiscus sabdariffa extracts (2020)
Title : Anti-aging potential and phytochemicals of Centella asiatica, Nelumbo nucifera, and Hibiscus sabdariffa extracts
Researcher : Monsicha Khuanekkaphan1, Chanai Noysang2, Warachate Khobjai3
Department : 1 Department of Health and Aesthetics, Thai Traditional Medicine College, Rajamangala University of Technology Thanyaburi, Pathum Thani, Thailand
2 Department of Innovation of Health Products, Thai Traditional Medicine College, Rajamangala University of Technology Thanyaburi, Pathum Thani, Thailand
3 Department of Applied Thai Traditional Medicine, Thai Traditional Medicine College, Rajamangala University of Technology Thanyaburi, Pathum Thani, Thailand
Abstract : Centella asiatica, Nelumbo nucifera Gaertn, and Hibiscus sabdariffa have been used as medicinal plants in Thailand. They are sources of phytochemicals that applications for esthetic and healthcare. The aim of this research was to examine the phytochemical constituents and anti-aging potential of these plants. The phytochemical compounds were performed using gas chromatography-mass spectrometry. The anti-aging activities were evaluated by 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,2′-azinobis (3-ethylbenzothiazoline-6-sunfonic acid) (ABTS), anti-collagenase, and anti-elastase assays. The main interest phytochemical compounds of ethanolic extracts of C. asiatica, N. nucifera, H. sabdariffa were ethanol, 2-(-Octadecenyloxy), γ-sitosterol and hexadecanoic acid, and ethyl ester, respectively. The DPPH half-maximal inhibitory concentration (IC50) results of C. asiatica, N. nucifera, and H. sabdariffa were 0.32 ± 0.01, 0.34 ± 0.00, and 0.35 ± 0.01 mg/mL, respectively. The ABTS result of H. sabdariffa extract showed high inhibitory activity at IC50of the extract was 0.62 ± 0.12 mg/mL. The percentage of collagenase inhibition of C. asiatica, N. nucifera, and H. sabdariffa at 1.0 mg/mL was 78.13 ± 4.42, 85.94 ± 2.21, and 90.63 ± 0.00, respectively. The C. asiatica extract had a high percentage of elastase inhibition. Consequently, these research results suggest that phytochemicals may also provide a range of esthetic and health benefits. The phytochemical constituent could be used as anti-aging active ingredient for cosmetic and pharmaceutical industrials.
Keywords: Anti-aging, Centella asiatica, Hibiscus sabdariffa, Nelumbo nucifera, phytochemical
Link to Academic article: DOI: 10.4103/japtr.JAPTR_79_20
Journal : this link is disabled,
Bibliography : Khuanekkaphan, M., Noysang, C., & Khobjai W. (2020). Anti-aging potential and phytochemicals of Centella asiatica, Nelumbo nucifera, and Hibiscus sabdariffa extracts. J Adv Pharm Technol Res, 11(4), 174-178. Retrieved from https://www.japtr.org/text.asp?2020/11/4/174/297699
Anticholinergic discontinuation and cognitive functions in patients/ Thanompong Sathienluckana
Abstract
Introduction: Cognitive impairment is a core feature and shows the highest impact on functional outcome in patients with schizophrenia. There have been no previous studies investigating the role of the pharmacist in a multidisciplinary team on cognitive outcomes in patients with schizophrenia.
Purpose: We evaluated the impact of pharmacist intervention on cognitive outcomes in patients with schizophrenia by focusing on anticholinergic discontinuation.
Patients and methods: A prospective, open-label, randomized, controlled study was conducted. Patients with schizophrenia were randomly assigned to either the pharmacist intervention or usual care groups. In the pharmacist intervention group, the pharmacist identified drug-related problems (DRPs) and provided a pharmacotherapy suggestion, while there was no intervention in the usual care group. The primary outcome was mean change from baseline of executive function by using Wisconsin Card Sorting Test (WCST) perseverative errors within the pharmacist intervention group at week 12.
Results: A total of 30 patients completed the study (13 in the pharmacist intervention group and 17 in the usual care group). WCST perseverative errors at the end of the study within the pharmacist intervention group improved significantly from baseline (P=0.003). DRPs at week 12 were reduced by 85.19% and 9.76% in the pharmacist intervention and usual care groups, respectively. The most common intervention was the discontinuation of anticholinergics in patients without extrapyramidal side effects.
Conclusion: Added-on pharmacist intervention in a multidisciplinary team could help to improve cognitive functions in patients with schizophrenia by reducing DRPs and optimizing the drug therapy regimen, especially for anticholinergic discontinuation.
Keywords: pharmacist intervention, cognitive functions, schizophrenia, anticholinergic
Link to Publication: https://www.dovepress.com/anticholinergic-discontinuation-and-cognitive-functions-in-patients-wi-peer-reviewed-fulltext-article-IPRP
Bibliography :Thaompong Sathienluckana, Weerapon Unaharassamee, Chuthamanee Suthisisang, Orabhorn Suanchang, Thanarat Suansanae. (2018). Anticholinergic discontinuation and cognitive functions in patients with schizophrenia: a pharmacist-physician collaboration in the outpatient departmentx. Dove Medical Press, 409-414.
Antimicrobial Dosing Concepts in Patients with Reduced Kidney Function (2560)
Antimicrobial Dosing Concepts in Patients with Reduced Kidney Function (2560)
ผู้เขียนบทความ: ผู้ช่วยศาสตราจารย์ ดร. ภก. วีรชัย ไชยจามร
บทคัดย่อ:
การใช้ยาต้านจุลชีพสำหรับการรักษาภาวะติดเชื้อ จำเป็นต้องพิจารณาจากปัจจัยหลายด้าน ทั้งจากยาต้านจุลชีพและสภาวะผู้ป่วย เชื้อก่อโรค รวมถึงบริเวณที่ติดเชื้อ ในอดีต ปัจจัยสำคัญที่เป็นตัวกำหนดในการเลือกยาต้านจุลชีพได้แก่ เชื้อก่อโรค ค่า minimum inhibitory concentration (MIC) และความไวของเชื้อ (in vitro antimicrobial susceptibility patterns) แต่การพิจารณาจากปัจจัยดังกล่าวข้างต้นยังไม่เพียงพอในการดูแลผู้ป่วยภาวะติดเชื้อให้เหมาะสมและมีประสิทธิภาพ ปัจจัยอื่นที่ต้องพิจารณาร่วมด้วยคือ การมีระดับยาที่เพียงพอในบริเวณที่เกิดภาวะติดเชื้อ (infection site) และพยาธิสภาพของผู้ป่วยที่ส่งผลต่อเภสัชจลนศาสตร์และเภสัชพลศาสตร์ของยาต้านจุลชีพที่เลือกใช้ เพื่อให้เกิดผลลัพธ์ในการรักษาที่ดี คือ การหายจากภาวะติดเชื้อ การป้องกันการเกิดเชื้อดื้อยา และผู้ป่วยไม่เกิดพิษจากการได้รับยาต้านจุลชีพในขนาดที่ไม่เหมาะสม
คำสำคัญ:
Link to Academic article: Antimicrobial Dosing Concepts in Patients with Reduced Kidney Function
Clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy (2014)
Abstract
We conducted a cross sectional study of the outpatient medical records of 1,000 HIV-infected patients receiving antiretroviral therapy (ART) in 2011 to determine the incidence of clinically significant drug interactions (CSDI). The severities of the CSDI were graded following the Micromedex® 2.0 database and the Department of Health and Human Services (DHHS) 2012 HIV treatment guidelines. Three hundred thirty-five patients (34%) had 554 episodes of CSDI. Of which 337 episodes (61%), 163 episodes (29%) and 54 episodes (10%) had grades 2, 3 and 4 severity CSDI, respectively. The CSDI were caused by protease inhibitor (PI)-based drug regimens in 79%, by efavirenz-based regimens in 34% and by nevirapine-based regimens in 10% (p<0.001). The three most common grade 4 CSDI were: a PI with simvastatin (n=24), simvastatin with gemfibrozil (n=24) and didanosine with allopurinol (n=2). The three most common grade 3 CSDI were: a PI with a statin drug except simvastatin (n=56), fenofibrate with a statin drug (n=28) and amlodipine with simvastatin (n=14). On multivariate analysis, risk factors associated with CSDI were: receiving a PI-based regimen (OR 14.44; 95%CI: 9.10-22.88), having dyslipidemia (OR 3.94; 95%CI: 1.89-8.21), having >5 items prescribed at a time (OR 1.80; 95%CI: 1.23-2.63), seeing a doctor >4 times a year (OR 1.72; 95%CI: 1.20-2.46), having hypertension (OR 0.60; 95%CI: 0.37-0.98), having a duration of receiving ART of >5 years (OR 0.46; 95%CI: 0.28-0.77) and having a CD4 count of >200 cells/mm3 (OR 0.46; 95%CI: 0.26-0.84). CSDI were common among HIV-infected patients receiving ARV in our outpatient clinic. Patients having a low CD4 count, having dyslipidemia, receiving PI-based ART, having a frequent number of visits per year and having a large number of items prescribed at each visit had a greater chance of a CSDI.
Keywords: antiretroviral, drug interaction, HIV, Thailand
Link to Publication: http://www.tm.mahidol.ac.th/seameo/journal-45-5-2014.html / in Scopus
Bibliography : So-Ngern, A., Montakantikul, P. & Manosuthi, W. (2014). Clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy. Southeast Asian J Trop Med Public Health, 45(5), 1023-1031.
Comparative in vitro activity of sitafloxacin against multidrug-resistant and carbapenem-resistant acinetobacter baumannii clinical isolates in Thailand (2020)
Title : Comparative in vitro activity of sitafloxacin against multidrug-resistant and carbapenem-resistant acinetobacter baumannii clinical isolates in Thailand
Researcher : Taniya Paiboonvong1,Vipavee Rodjun2,Jantana Houngsaitong1,Mullika Chomnawang3,Preecha Montakantikul2,Suvatna Chulavatnatol2*
1 Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand
2 Faculty of Pharmacy, Siam University, Bangkok, Thailand
3 Department of Microbiology, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand
ฐานข้อมูลงานวิจัย มหาวิทยาลัยสยาม : –
Link to article: Pharmaceutical Sciences Asia, 2020, 47(1), pp. 37–42 https://pharmacy.mahidol.ac.th/journal/journalabstractDetail.php?jvol=47&jpart=1&jconnum=4
Journal :Pharmaceutical Sciences Asia/ Scopus
Citation : Paiboonvong, T., Rodjun, V., Houngsaitong, J., Chomnawang, M., Montakantikul,P., & Chulavatnatol, S. (2020). Comparative in vitro activity of sitafloxacin against multidrug-resistant and carbapenem-resistant acinetobacter baumannii clinical isolates in Thailand. Pharmaceutical Sciences Asia, 47(1), 37–42. https://doi.org/10.29090/psa.2020.01.019.0012
Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia (2021)
Title : Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
Researcher : Sathienluckana, T., Tiangpattanawong, P., Chaiyasukthananoan, K., Jittayanan, P., Sawetwangsing, H., Puchsaka, P.
Abstract : Background
Long-acting injectable (LAI) antipsychotics are used as a monotherapy in patients with schizophrenia. However, the combination of LAI and oral antipsychotics is commonly used in clinical practice, despite there being very limited studies investigating the efficacy and safety of this combination compared with LAI antipsychotic monotherapy.
Objective
To study the efficacy and safety of LAI antipsychotic monotherapy compared with the combination of LAI and oral antipsychotics in patients with schizophrenia.
Methods
This study was a retrospective cohort study, which classified eligible patients into two groups: the LAI antipsychotic monotherapy group and the combination of LAI and oral antipsychotic group. The primary outcome was hospitalization between groups. The duration of the study was 2 years.
Results
In total, 86 patients completed the study and were analysed (LAI antipsychotic monotherapy group: n = 25; combination of LAI and oral antipsychotic group: n = 61). There was no significant difference in hospitalization between the two groups (P = 1.000). For other outcomes, there were also no significant differences in both all-cause discontinuation (P = 0.667) and adverse drug reactions (P = 0.732) between the two groups.
Conclusion
The efficacy and safety of LAI antipsychotic monotherapy appeared similar to the combination of LAI and oral antipsychotics in patients with schizophrenia. Therefore, the combination of LAI and oral antipsychotics, which is commonly used in clinical practice, may not be necessary.
Link to article: doi: 10.1155/2021/8403986
Journal : Schizophr Res Treatment
Bibliography : Sathienluckana, T., Tiangpattanawong, P., Chaiyasukthananoan, K., Jittayanan, P., Sawetwangsing, H., & Pummangura, C. (Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia. this,
Comparison of the Effectiveness and Safety of Clozapine Between Once-Daily and Divided Dosing Regimen in Patients With Treatment-Resistant Schizophrenia (2023)
Title : Comparison of the Effectiveness and Safety of Clozapine Between Once-Daily and Divided Dosing Regimen in Patients With Treatment-Resistant Schizophrenia
Researcher : Thanompong Sathienluckana, Thaksin Jansing,Supakan Srisuriyakamon, Aunchalee thonkhunthod, Parsiri Sangsuwanto, Pholphat Losatiankij and Suttha Supanya
Link to article: Annals of Pharmacotherapy, 2023 Sep 24;10600280231201708. https://doi.org/10.1177/10600280231201708
Citation : Sathienluckana T, Jansing T, Srisuriyakamon S, Thonkhunthod A, Sangsuwanto S, Losatiankij P and Supanya S. (2023). Comparison of the effectiveness and safety of clozapine between once-daily and divided dosing regimen in patients with treatment-resistant schizophrenia. Annals of Pharmacotherapy, 10600280231201708. https://doi.org/10.1177/10600280231201708
Journal : Annals of Pharmacotherapy / in Scopus
ฐานข้อมูลงานวิจัย มหาวิทยาลัยสยาม : https://e-research.siam.edu/kb/comparison-of-the-effectiveness/